Phase II trial of perioperative chemotherapy for esophageal cancer
Phase 2
- Conditions
- esophageal cancer
- Registration Number
- JPRN-UMIN000020204
- Lead Sponsor
- Kyoto university hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Synchronous or metachronous (within 5 years) malignancies except for carcinoma in situ or mucosal tumors curatively treated with local therapy. 2) Active infection requiring systemic therapy. 3) Positive HBs antigen, or positive HCV antibody. 4) Pregnancy, possible pregnancy or breastfeeding. 5) Psychiatric disease. 6) Patients who need flucitosine, fenitoin or warfarin. 7) Poorly controlled diabetes mellitus 8) Severe pulmonary fibrosis or emphysema. 9) Serious angina or myocaedial infarcion within 3 months 10) Patients whom principle/sub-investigator judged ineligible to participate in this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Three-year relapse free survival
- Secondary Outcome Measures
Name Time Method Overall survival, time to treatment free survival, treatment completion rate, incidence of adverse events, incidence of treatment related death